A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

BMC Clinical Pathology

Volumn 13, Issue 1, 2013, Pages

  Kobayashi, Takayuki ^a   Iwaya, Keiichi ^a   Moriya, Tomoyuki ^a   Yamasaki, Tamio ^a   Tsuda, Hitoshi ^b   Yamamoto, Junji ^a   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

IHC panel; Ki67 labeling index; Luminal type breast cancer; p53

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FADROZOLE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; KI 67 ANTIGEN; METHOTREXATE; P CADHERIN; PROTEIN P53; TAMOXIFEN; TOREMIFENE; TRANSCRIPTION FACTOR GATA 3;

ADULT; ANTIBODY LABELING; ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUMINAL TYPE BREAST CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHENOTYPE; PREDICTION;

EID: 84873245504     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-13-5     Document Type: Article

References (38)

1. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Badve S, Nakshatri H, J Clin Pathol 2009 62 1 6 12 10.1136/jcp.2008.059899 18794199
2. Treatment of breast cancer. Hortobagyi GN, N Engl J Med 1998 339 14 974 984 10.1056/NEJM199810013391407 9753714 (Pubitemid 28455101)
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group, Lancet 1998 351 9114 1451 1467 9605801
4. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP, J Natl Cancer Inst 2006 98 18 1285 1291 10.1093/jnci/djj357 16985247 (Pubitemid 44530724)
5. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N, Lancet 2004 364 9437 858 868 10.1016/S0140-6736(04)16981-X 15351193 (Pubitemid 39221063)
6. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. N Engl J Med 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
7. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. J Natl Cancer Inst 2009 101 10 736 750 10.1093/jnci/djp082 19436038
8. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, et al. J Clin Oncol 2006 24 23 3726 3734 10.1200/JCO.2005.04.7985 16720680 (Pubitemid 46622311)
9. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Proc Natl Acad Sci USA 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
10. p53 and breast cancer, an update. Lacroix M, Toillon RA, Leclercq G, Endocr Relat Cancer 2006 13 2 293 325 10.1677/erc.1.01172 16728565 (Pubitemid 43886660)
11. Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. Calza S, Hall P, Auer G, Bjohle J, Klaar S, Kronenwett U, Liu ET, Miller L, Ploner A, Smeds J, et al. Breast Cancer Res 2006 8 4 34 10.1186/bcr1517 16846532 (Pubitemid 44057559)
12. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, et al. Breast Cancer Res 2008 10 5 74 10.1186/bcr2139 18771580
13. The molecular portraits of breast tumors are conserved across microarray platforms. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, et al. BMC Genomics 2006 7 96 10.1186/1471-2164-7-96 16643655 (Pubitemid 43786485)
14. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F, et al. Breast Cancer Res 2008 10 4 65 10.1186/bcr2124 18662380
15. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S, Jpn J Cancer Res 1991 82 7 835 840 10.1111/j.1349-7006.1991. tb02710.x 1679056
16. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, et al. Clin Cancer Res 2006 12 4 1157 1167 10.1158/1078-0432.CCR-05-1029 16489069 (Pubitemid 43342504)
17. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S, J Clin Pathol 2008 61 3 327 332 18037662 (Pubitemid 351354239)
18. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer. Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D, Breast Cancer Res 2009 11 2 23 10.1186/bcr2249 19405945
19. Ki67 in breast cancer: prognostic and predictive potential. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA, Lancet Oncol 2010 11 2 174 183 10.1016/S1470-2045(09)70262-1 20152769
20. Ki67 protein: the immaculate deception? Brown DC, Gatter KC, Histopathology 2002 40 1 2 11 10.1046/j.1365-2559.2002.01343.x 11903593 (Pubitemid 34107377)
21. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E, MacGrogan G, Braye SG, Ohlschlegel C, et al. J Clin Oncol 2008 26 34 5569 5575 10.1200/JCO.2008.17.0829 18981464
22. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis. Kobayashi T, Tsuda H, Moriya T, Yamasaki T, Kikuchi R, Ueda S, Omata J, Yamamoto J, Matsubara O, Breast Cancer Res Treat 2010 123 3 733 745 10.1007/s10549-009-0672-y 20020198
23. General rules for clinical and pathological recording of breast cancer 2005. Sakamoto G, Inaji H, Akiyama F, Haga S, Hiraoka M, Inai K, Iwase T, Kobayashi S, Sano M, Sato T, et al. Breast Cancer 2005 12 Suppl 1 S27 16410755
24. Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Millar EK, Graham PH, McNeil CM, Browne L, O'Toole SA, Boulghourjian A, Kearsley JH, Papadatos G, Delaney G, Fox C, et al. Br J Cancer 2011 105 2 272 280 10.1038/bjc.2011.228 21712826
25. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer. Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Bohm G, Jasarevic Z, et al. Clin Cancer Res 2011 17 24 7828 7834 10.1158/1078-0432.CCR-11-1846 21998336
26. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Alba E, Calvo L, Albanell J, De la Haba JR, Arcusa Lanza A, Chacon JI, Sanchez-Rovira P, Plazaola A, Lopez Garcia-Asenjo JA, Bermejo B, et al. Ann Oncol 2012 23 12 3069 3074 10.1093/annonc/mds132 22674146
27. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M, Clin Cancer Res 1996 2 1 147 154 9816101 (Pubitemid 26046500)
28. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pinto AE, Andre S, Laranjeira C, Soares J, Pathology 2005 37 1 45 50 10.1080/00313020400011250 15875733 (Pubitemid 40314448)
29. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al. J Clin Oncol 2007 25 1 118 145 17159189 (Pubitemid 350003059)
30. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N, J Clin Oncol 2011 29 25 3366 3373 10.1200/JCO.2011.35.0868 21768458
31. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. N Engl J Med 2001 344 11 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
32. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MC, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, et al. J Clin Oncol 2006 24 19 3039 3047 10.1200/JCO.2006.05.6564 16809728 (Pubitemid 46638938)
33. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N, Clin Cancer Res 2008 14 20 6602 6609 10.1158/1078-0432.CCR-08-0647 18927301
34. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F, Virchows Arch 2005 447 4 688 694 10.1007/s00428-005- 0010-7 16012853 (Pubitemid 41571183)
35. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. JAMA 2006 295 21 2492 2502 10.1001/jama.295.21.2492 16757721 (Pubitemid 43854964)
36. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Tan DS, Marchio C, Jones RL, Savage K, Smith IE, Dowsett M, Reis-Filho JS, Breast Cancer Res Treat 2008 111 1 27 44 10.1007/s10549-007-9756-8 17922188 (Pubitemid 352009225)
37. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? Brenton JD, Carey LA, Ahmed AA, Caldas C, J Clin Oncol 2005 23 29 7350 7360 10.1200/JCO.2005.03.3845 16145060 (Pubitemid 46202348)
38. Triple-negative breast cancer: risk factors to potential targets. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA, Clin Cancer Res 2008 14 24 8010 8018 10.1158/1078-0432.CCR-08-1208 19088017